Switch to:
PDL BioPharma, Inc. (NAS:PDLI)
EV/EBIT
4.10 (As of Today)

EV/EBIT ratio is calculated as enterprise value divided by its EBIT. As of today, PDL BioPharma, Inc.'s enterprise value is $1,644.3 Mil. PDL BioPharma, Inc.'s operating income for the trailing twelve months (TTM) ended in Dec. 2013 was $407.5 Mil. Therefore, PDL BioPharma, Inc.'s EV/EBIT ratio for today is 4.10.

PDLI' s 10-Year EV/EBIT Range
Min: 2.1   Max: 508
Current: 4.1

2.1
508

During the past 13 years, the highest EV/EBIT Ratio of PDL BioPharma, Inc. was 508.00. The lowest was 2.10. And the median was 4.90.

PDLI's EV/EBITis ranked higher than
88% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. PDLI: 4.10 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt). PDL BioPharma, Inc.'s enterprise value for the quarter that ended in Dec. 2013 was $1,476.8 Mil. PDL BioPharma, Inc.'s Operating Income for the trailing twelve months (TTM) ended in Dec. 2013 was $407.5 Mil. PDL BioPharma, Inc.'s Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2013 was 27.62%.


Definition

PDL BioPharma, Inc.'s EV/EBIT for today is calculated as:

EV/EBIT=Enterprise Value (Today)/Operating Income (TTM)
=1644.302/407.529
=4.03

PDL BioPharma, Inc.'s current Enterprise Value is $1,644.3 Mil.
PDL BioPharma, Inc.'s Operating Income for the trailing twelve months (TTM) ended in Dec. 2013 was 84.661 (Mar. 2013 ) + 136.834 (Jun. 2013 ) + 89.389 (Sep. 2013 ) + 96.645 (Dec. 2013 ) = $407.5 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

This is a more accurate valuation of companies' operation because it consider the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt).

PDL BioPharma, Inc.'s Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2013 is calculated as:

Earnings Yield (Joel Greenblatt) (Q: Dec. 2013 )=Operating Income (TTM)/Enterprise Value (Q: Dec. 2013 )
=407.529/1476.8336
=27.59 %

PDL BioPharma, Inc.'s Enterprise Value for the quarter that ended in Dec. 2013 was $1,476.8 Mil.
PDL BioPharma, Inc.'s Operating Income for the trailing twelve months (TTM) ended in Dec. 2013 was 84.661 (Mar. 2013 ) + 136.834 (Jun. 2013 ) + 89.389 (Sep. 2013 ) + 96.645 (Dec. 2013 ) = $407.5 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Related Terms

Enterprise Value, Operating Income, Earnings Yield (Joel Greenblatt)


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

PDL BioPharma, Inc. Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
ev2ebit 0.000.0011.937.934.514.195.393.103.283.62

PDL BioPharma, Inc. Quarterly Data

Sep11Dec11Mar12Jun12Sep12Dec12Mar13Jun13Sep13Dec13
ev2ebit 4.093.103.193.033.613.283.152.992.843.62
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide